TP53 and extranodal nasal NK/T cell lymphoma: Concordantly, we found 50% (3/6) of TP53-mutated NKTCL patients have chromothripsis, whereas only 18.5% (12/65) of those NKTCL patients with wild-type TP53 have chromothripsis, underscoring the risk of TP53 mutation in triggering nuclear catastrophe.